Share
Market Research Report

PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Drug ClassLutetium (Lu-177) · Yttrium-90 · Indium-111 · and others
  • By Disease IndicationPancreatic - Neuroendocrine Tumor · Gastrointestinal Tract - Neuroendocrine Tumor and Others
  • By Distribution ChannelHospital Pharmacies · Retail Pharmacies · Online Pharmacies
  • By RegionNorth America · Latin America · Europe · Asia Pacific · Middle East · and Africa
  • Published In28 Apr 2026
  • Report CodeCMI2731
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Detailed Segmentation:

  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)

    • Lutetium (Lu-177)-based
    • Yttrium-90
    • Indium-111
    • Others
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)

    • Pancreatic - Neuroendocrine Tumor
    • Gastrointestinal Tract - Neuroendocrine Tumor
    • Others
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Region (Revenue, USD Mn, 2021 - 2033)

    • North America
      • By Drug Type:
        • Lutetium (Lu-177)-based
        • Yttrium-90
        • Indium-111
        • Others
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Lutetium (Lu-177)-based
        • Yttrium-90
        • Indium-111
        • Others
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Lutetium (Lu-177)-based
        • Yttrium-90
        • Indium-111
        • Others
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Lutetium (Lu-177)-based
        • Yttrium-90
        • Indium-111
        • Others
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Lutetium (Lu-177)-based
        • Lutetium (Lu-177)-based
        • Yttrium-90
        • Indium-111
        • Others
      • By Disease Indication:
        • Pancreatic - Neuroendocrine Tumor
        • Gastrointestinal Tract - Neuroendocrine Tumor
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa